தற்காலிக ஆய்வகங்கள் இன்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Worldwide Genomic Cancer Panel and Profiling Industry to 2025 - Featuring Anchor, Bioarray Genetics and Burning Rock Among Others
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Worldwide Genomic Cancer Panel and Profiling Industry to 2025 - Featuring Anchor, Bioarray Genetics and Burning Rock Among Others
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
7 Molecular Diagnostics Recent Developments
7.1 Recent Developments - Importance and How to Use This Section
7.1.1 Importance of These Developments
7.1.2 How to Use This Section
7.2 Nucleix to Invest in Early-Stage Lung Cancer Dx
7.3 Invitae to Acquire Genosity for $200M
7.4 Bio-Techne Obtains CE Mark for Exosomal Liquid Biopsy Prostate Test
7.5 Agilent Technologies to Acquire Liquid Biopsy Firm Resolution Bioscience
7.6 Natera Revenues Grow 35 Percent
7.7 AnchorDx Closes $40M Financing Round
7.8 Exact Sciences Strategy for End-to-End Cancer Testing
7.9 Genomics England: Whole Genome Sequencing for Cancer Patients to Launch
7.10 Singlera Genomics Closes $150M Funding for Cancer Screening
7.11 Biocartis GeneproDx, Endpoint Health Collaborate on Tests for Idylla Platform
E-Mail
IMAGE: Dr. O Dwyer is co-leading the largest precision medicine cancer clinical trial to date, NCI-MATCH, with 39 single-arm phase II treatment arms. Researchers are locating patients for the 12 remaining arms. view more
Credit: University of Pennsylvania
The NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) cancer clinical trial is expanding with the opening of a new treatment arm. The addition, Arm Z1M, is a single-arm phase II study of a two-drug combination, relatlimab and nivolumab, both immunotherapies. To be eligible, patients must have mismatch repair deficiency on genomic testing and tumors that express the
LAG-3 protein, a cancer immunotherapy target. The cancer must also have progressed on anti-PD-1/PD-L1 immunotherapy. The addition brings the number of available treatment arms in NCI-MATCH to 12. The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and the National Cancer Institute (NCI), part of the National Institutes of Health, are co-leading
Global Human Gene Sequencing Market Report 2021-2025: COVID-19 Pandemic has Put the Market on Pause
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.